Physician profile
Karin Chen
NPI 1477877611
$51,310.88
in general payments reported to CMS, 2019-2025
13 companies · $444 in 2025
The $444 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $2,000 · 2022: $36K · 2023: $2,465 · 2024: $11K · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,750 · Honoraria: $2,025 · Food and Beverage: $1,536 · Travel and Lodging: $1,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,750.00 |
| Honoraria | $2,025.00 |
| Food and Beverage | $1,535.78 |
| Travel and Lodging | $1,114.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $20,975.68 | 2020-2023 | Actimmune |
| Takeda Pharmaceuticals U.S.A., INC. | $18,937.01 | 2022 | |
| Amgen INC. | $7,923.33 | 2024-2025 | Actimmune |
| Pharming Healthcare, INC. | $2,587.31 | 2024 | Joenja |
| Csl Behring | $195.36 | 2023 | Hizentra |
| Leadiant Biosciences, INC. | $150.00 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $142.41 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $140.09 | 2024-2025 | Orladeyo |
| Regeneron Healthcare Solutions, INC. | $92.17 | 2024 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $74.74 | 2025 | Fasenra |
| Sobi, INC | $62.64 | 2023 | |
| Janssen Biotech, INC. | $30.14 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.